Amalgamated Financial’s Rhythm Pharmaceuticals RYTM Stock Holding History

Amalgamated Financial’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$61K	Buy	+5,326	New	+$46.7K	﹤0.01%	2326

Other funds holding RYTM

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Amalgamated Financial's RYTM Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Rhythm Pharmaceuticals (RYTM) in Q1 2022: 5,326 shares worth $61K. The stake represents ﹤0.01% of the portfolio and ranks #2326 among its holdings.

111 funds tracked by Wall St. Rank hold RYTM as of Q1 2022.

Amalgamated Financial held 5,326 shares of Rhythm Pharmaceuticals worth $61K as of Q1 2022.
Rhythm Pharmaceuticals was a new Amalgamated Financial position in Q1 2022.
Rhythm Pharmaceuticals made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2326 holding.
111 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.